OrbiMed Closes A $950m Fund As Biotech VC Surge Continues
This article was originally published in Scrip
Executive Summary
The health care-focused venture capital firm OrbiMed has raised its largest VC fund to date totaling $950m and if prior investment patterns are repeated as much as $760m of that could be invested in companies focused on the development of drugs or gene therapies.
You may also be interested in...
eFFECTOR Translates $38.6m Into Five Cancer Clinical Trials
The firm's $38.6m in Series C cash will fund additional clinical trials for lead translation regulator eFT508, support the first human trial for eFT226 and advance a third program into preclinical studies.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.